Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;42(7):779-789.
doi: 10.1200/JCO.22.02470. Epub 2023 Nov 17.

Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer

Affiliations

Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer

Charlotte C Gard et al. J Clin Oncol. .

Abstract

Purpose: We extended the Breast Cancer Surveillance Consortium (BCSC) version 2 (v2) model of invasive breast cancer risk to include BMI, extended family history of breast cancer, and age at first live birth (version 3 [v3]) to better inform appropriate breast cancer prevention therapies and risk-based screening.

Methods: We used Cox proportional hazards regression to estimate the age- and race- and ethnicity-specific relative hazards for family history of breast cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for invasive breast cancer in the BCSC cohort. We evaluated calibration using the ratio of expected-to-observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC).

Results: We analyzed data from 1,455,493 women age 35-79 years without a history of breast cancer. During a mean follow-up of 7.3 years, 30,266 women were diagnosed with invasive breast cancer. The BCSC v3 model had an E/O of 1.03 (95% CI, 1.01 to 1.04) and an AUROC of 0.646 for 5-year risk. Compared with the v2 model, discrimination of the v3 model improved most in Asian, White, and Black women. Among women with a BMI of 30.0-34.9 kg/m2, the true-positive rate in women with an estimated 5-year risk of 3% or higher increased from 10.0% (v2) to 19.8% (v3) and the improvement was greater among women with a BMI of ≥35 kg/m2 (7.6%-19.8%).

Conclusion: The BCSC v3 model updates an already well-calibrated and validated breast cancer risk assessment tool to include additional important risk factors. The inclusion of BMI was associated with the largest improvement in estimated risk for individual women.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Change in estimated risk for invasive breast cancer by BMI. BCSC, Breast Cancer Surveillance Consortium; v2, version 2; v3, version 3.

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. - PubMed
    1. Gail MH, Pfeiffer RM. Breast cancer risk model requirements for counseling, prevention, and screening. J Natl Cancer Inst. 2018;110:994–1002. - PMC - PubMed
    1. US Preventive Services Task Force. Davidson KW, Krist AH, et al. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019;322:857–867. - PubMed
    1. Tice JA, Miglioretti DL, Li CS, et al. Breast density and benign breast disease: Risk assessment to identify women at high risk of breast cancer. J Clin Oncol. 2015;33:3137–3143. - PMC - PubMed
    1. Eroglu I, Sevilimedu V, Park A, et al. Accuracy of the Breast Cancer Surveillance Consortium model among women with LCIS. Breast Cancer Res Treat. 2022;194:257–264. - PMC - PubMed

Supplementary concepts